Indication
Multiple myeloma
Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of abnormal plasma cells primarily within the bone marrow. Read more about Multiple myeloma
167 drugs 90 manufacturers
Drugs that treat it
Common Multiple myeloma therapies.
ABECMA (idecabtagene vicleucel)
CARVYKTI (ciltacabtagene autoleucel)
BICNU (carmustine)
THALOMID (thalidomide)
REVLIMID (lenalidomide)
POMALYST (pomalidomide)
ALKERAN (AS HCL) (melphalan HCl)
ABECMA (idecabtagene vicleucel)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonMultiple myeloma is a hematologic malignancy characterized by the clonal proliferation of abnormal plasma cells primarily within the bone marrow.
It predominantly affects older adults and involves the hematopoietic and skeletal systems.
Pathophysiologically, the malignant expansion disrupts normal hematopoiesis and stimulates osteoclastic bone resorption while suppressing osteoblastic activity, accompanied by the overproduction of monoclonal immunoglobulins or free light chains.
Clinically, this leads to classic manifestations of end-organ damage, including osteolytic bone lesions, pathologic fractures, hypercalcemia, renal impairment, cytopenias such as anemia, and heightened susceptibility to infection.
- cuanschutz.edu
Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of abnormal plasma cells primarily within the bone marrow
- nih.gov
Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of abnormal plasma cells primarily within the bone marrow Pathophysiologically, the malignant expansion disrupts normal hematopoiesis and stimulates osteoclastic bone resorption while suppressing osteoblastic activity, accompanied by the overproduction of monoclonal immunoglobulins or free light chains
- cdc.gov
It predominantly affects older adults and involves the hematopoietic and skeletal systems Clinically, this leads to classic manifestations of end-organ damage, including osteolytic bone lesions, pathologic fractures, hypercalcemia, renal impairment, cytopenias such as anemia, and heightened susceptibility to infection
- nih.gov
It predominantly affects older adults and involves the hematopoietic and skeletal systems Pathophysiologically, the malignant expansion disrupts normal hematopoiesis and stimulates osteoclastic bone resorption while suppressing osteoblastic activity, accompanied by the overproduction of monoclonal immunoglobulins or free light chains Clinically, this leads to classic manifestations of end-organ damage, including osteolytic bone lesions, pathologic fractures, hypercalcemia, renal impairment, cyto...
- nih.gov
Pathophysiologically, the malignant expansion disrupts normal hematopoiesis and stimulates osteoclastic bone resorption while suppressing osteoblastic activity, accompanied by the overproduction of monoclonal immunoglobulins or free light chains
- myeloma.org
Clinically, this leads to classic manifestations of end-organ damage, including osteolytic bone lesions, pathologic fractures, hypercalcemia, renal impairment, cytopenias such as anemia, and heightened susceptibility to infection
Personalize your experience
Follow Multiple myeloma and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.